secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2025-09-10T23:59:59+00:00
Accession:  0001567264-25-000093
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics pauses INVINCIBLE-4 enrollment after skin irritation; first Cohort A patient achieves pCR
--------------------------------------------------------------------------------

- First patient in Cohort A achieved pathological complete response after two INT230-6 doses plus immunochemotherapy.
- Cohort A patients received INT230-6 eight days apart followed by standard-of-care immunochemotherapy.
- Safety profile described as favorable, but localized skin irritation near tumor site observed in some patients.
- Enrollment paused to evaluate data and implement adjustments before reopening.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000156726425000093/0001567264-25-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000156726425000093/intensity-20250910.htm
  HTML page:      https://secwatch.observer/filing/0001567264-25-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer